Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Other
|VRX||Valeant Pharmaceuticals International, Inc.||0.00%||29.07||14.1%||$171.05m|
|JAZZ||Jazz Pharmaceuticals Plc||0.00%||179.17||2.2%||$142.15m|
|HZNP||Horizon Therapeutics Plc||0.00%||92.14||5.5%||$124.53m|
|BHC||Bausch Health Cos., Inc.||0.00%||29.07||0.0%||$91.68m|
|SAVA||Cassava Sciences, Inc.||0.00%||40.92||0.0%||$55.78m|
|UTHR||United Therapeutics Corp.||0.00%||197.87||14.0%||$55.65m|
|PRGO||Perrigo Co. Plc||-0.09%||45.82||6.9%||$49.71m|
|SAGE||SAGE Therapeutics, Inc.||0.00%||70.86||7.6%||$33.60m|
|PCRX||Pacira Biosciences, Inc.||0.00%||62.21||9.9%||$30.64m|
|AXSM||Axsome Therapeutics, Inc.||0.00%||58.42||1.9%||$26.79m|
|RVMD||Revolution Medicines, Inc.||0.00%||31.99||0.0%||$23.38m|
MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. Its drug candidates include Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.